News Agency
The Times

Skyhawk Therapeutics Receives Australian Regulatory Approval to Extend SKY-0515 Treatment Duration in Phase 1 Huntington's Disease Patient Trial

  • Written by PR Newswire
Skyhawk Therapeutics Receives Australian Regulatory Approval to Extend SKY-0515 Treatment Duration in Phase 1 Huntington's Disease Patient Trial

Australian Human Research Ethics Committees approves SKY-0515 treatment for up to 12 weeks in the company's ongoing Phase 1 trial in patients with Huntington's Disease

Volumetric MRI measurement is also approved as exploratory study endpoint

BOSTON, Dec. 10, 2024 /PRNewswire/ --  Skyhawk Therapeutics, Inc., a clinical-stage biotechnology...

Read more: Skyhawk Therapeutics Receives Australian Regulatory Approval to Extend SKY-0515 Treatment Duration...

Google Ads Agency Sydney: How to Generate More Qualified Leads With Paid Search

When someone searches Google for a service they need immediately, appearing at the right moment can be extremely valuable. Unlike many traditional marketing channels, paid search can place a business in front of people who are already researching a product... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion